360 related articles for article (PubMed ID: 27119500)
1. Proteomics and peptidomics: moving toward precision medicine in urological malignancies.
Di Meo A; Pasic MD; Yousef GM
Oncotarget; 2016 Aug; 7(32):52460-52474. PubMed ID: 27119500
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist.
Kim J; Jin P; Yang W; Kim WJ
Investig Clin Urol; 2020 Nov; 61(6):539-554. PubMed ID: 33135400
[TBL] [Abstract][Full Text] [Related]
3. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
[TBL] [Abstract][Full Text] [Related]
5. Urinary Peptidomic Biomarkers in Kidney Diseases.
Sirolli V; Pieroni L; Di Liberato L; Urbani A; Bonomini M
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877774
[TBL] [Abstract][Full Text] [Related]
6. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.
Huang R; Chen Z; He L; He N; Xi Z; Li Z; Deng Y; Zeng X
Theranostics; 2017; 7(14):3559-3572. PubMed ID: 28912895
[TBL] [Abstract][Full Text] [Related]
8. Biomarker discovery by proteomics-based approaches for early detection and personalized medicine in colorectal cancer.
Corbo C; Cevenini A; Salvatore F
Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 28019089
[TBL] [Abstract][Full Text] [Related]
9. Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics.
Chen YT; Tsai CH; Chen CL; Yu JS; Chang YH
J Food Drug Anal; 2019 Apr; 27(2):387-403. PubMed ID: 30987711
[TBL] [Abstract][Full Text] [Related]
10. Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.
Latosinska A; Frantzi M; Vlahou A; Merseburger AS; Mischak H
Proteomics Clin Appl; 2018 Mar; 12(2):. PubMed ID: 28980455
[TBL] [Abstract][Full Text] [Related]
11. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
12. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
13. Probing the colorectal cancer proteome for biomarkers: Current status and perspectives.
Lee PY; Chin SF; Low TY; Jamal R
J Proteomics; 2018 Sep; 187():93-105. PubMed ID: 29953962
[TBL] [Abstract][Full Text] [Related]
14. The application of proteomics in different aspects of hepatocellular carcinoma research.
Xing X; Liang D; Huang Y; Zeng Y; Han X; Liu X; Liu J
J Proteomics; 2016 Aug; 145():70-80. PubMed ID: 27072111
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma.
Zhong L; Liu Y; Wang K; He Z; Gong Z; Zhao Z; Yang Y; Gao X; Li F; Wu H; Zhang S; Chen L
BMC Cancer; 2018 Sep; 18(1):911. PubMed ID: 30241505
[TBL] [Abstract][Full Text] [Related]
16. High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis.
Lin L; Zheng J; Yu Q; Chen W; Xing J; Chen C; Tian R
J Proteomics; 2018 Mar; 174():9-16. PubMed ID: 29278786
[TBL] [Abstract][Full Text] [Related]
17. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer.
Ma H; Chen G; Guo M
Proteomics Clin Appl; 2016 Apr; 10(4):503-15. PubMed ID: 26616366
[TBL] [Abstract][Full Text] [Related]
19. Positional proteomics in the era of the human proteome project on the doorstep of precision medicine.
Eckhard U; Marino G; Butler GS; Overall CM
Biochimie; 2016 Mar; 122():110-8. PubMed ID: 26542287
[TBL] [Abstract][Full Text] [Related]
20. Proteomics in prostate cancer biomarker discovery.
Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
